BACKGROUND: Parkinson's disease (PD) is characterized by the selective loss of dopaminergic neurons in the midbrain. The pathogenesis of PD is not fully understood but is likely caused by a combination of genetic and environmental factors. Several genes are associated with the onset and progression of familial PD. There is increasing evidence that leucine-rich repeat kinase 2 (LRRK2) plays a significant role in PD pathophysiology. SUMMARY: Many studies have been conducted to elucidate the functions of LRRK2 and identify effective LRRK2 inhibitors for PD treatment. In this review, we discuss the role of LRRK2 in PD and recent progress in the use of LRRK2 inhibitors as therapeutic agents. Key Messages: LRRK2 plays a significant role in the pathophysiology of PD, and pharmacological inhibition of LRRK2 has become one of the most promising potential therapies for PD. Further research is warranted to determine the functions of LRRK2 and expand the applications of LRRK2 inhibitors in PD treatment.
BACKGROUND:Parkinson's disease (PD) is characterized by the selective loss of dopaminergic neurons in the midbrain. The pathogenesis of PD is not fully understood but is likely caused by a combination of genetic and environmental factors. Several genes are associated with the onset and progression of familial PD. There is increasing evidence that leucine-rich repeat kinase 2 (LRRK2) plays a significant role in PD pathophysiology. SUMMARY: Many studies have been conducted to elucidate the functions of LRRK2 and identify effective LRRK2 inhibitors for PD treatment. In this review, we discuss the role of LRRK2 in PD and recent progress in the use of LRRK2 inhibitors as therapeutic agents. Key Messages: LRRK2 plays a significant role in the pathophysiology of PD, and pharmacological inhibition of LRRK2 has become one of the most promising potential therapies for PD. Further research is warranted to determine the functions of LRRK2 and expand the applications of LRRK2 inhibitors in PD treatment.
Authors: Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth Journal: J Neurochem Date: 2021-10-03 Impact factor: 5.546
Authors: Nicola Whiffin; Irina M Armean; Aaron Kleinman; Jamie L Marshall; Eric V Minikel; Julia K Goodrich; Nicholas M Quaife; Joanne B Cole; Qingbo Wang; Konrad J Karczewski; Beryl B Cummings; Laurent Francioli; Kristen Laricchia; Anna Guan; Babak Alipanahi; Peter Morrison; Marco A S Baptista; Kalpana M Merchant; James S Ware; Aki S Havulinna; Bozenna Iliadou; Jung-Jin Lee; Girish N Nadkarni; Cole Whiteman; Mark Daly; Tõnu Esko; Christina Hultman; Ruth J F Loos; Lili Milani; Aarno Palotie; Carlos Pato; Michele Pato; Danish Saleheen; Patrick F Sullivan; Jessica Alföldi; Paul Cannon; Daniel G MacArthur Journal: Nat Med Date: 2020-05-27 Impact factor: 53.440